Home › Companies › SYNDAX PHARMACEUTICALS INC. › 2023-2024

SYNDAX PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and SYNDAX PHARMACEUTICALS INC.’s Form 8-K, filed May 15, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.

5Ballot items
217Asset managers
1,261Fund votes
May 15, 2024Meeting date

Results at a glance

Meeting of May 15, 2024: 5 items on SYNDAX PHARMACEUTICALS INC.’s Form 8-K, filed May 15, 2024: 5 without a stated outcome.

Material dissent

Elect Director: Jennifer Jarrett 63% of votes cast Outcome not stated Director under 80%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore SYNDAX PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by SYNDAX PHARMACEUTICALS INC.

These tallies are SYNDAX PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 15, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

SYNDAX PHARMACEUTICALS INC. — official shareholder meeting results, meeting held May 15, 2024
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Martin H. Huber, M.D.	61,876,711	--	--	736,625	3,032,770	99%	Not verified	—
Elect Director: Jennifer Jarrett	39,491,936	--	--	23,121,400	3,032,770	63%	Not verified	—
Elect Director: William Meury	54,416,889	--	--	8,196,447	3,032,770	87%	Not verified	—
2. Advisory vote on executive compensation	46,228,421	16,304,796	80,119	--	3,032,770	74%	Not verified	—
3. Ratification of selection of independent registered public accounting firm	65,371,337	253,270	21,499	--	--	99.6%	Not verified	—

Source: SYNDAX PHARMACEUTICALS INC., Form 8-K, filed with the SEC on May 15, 2024 — read the filing on EDGAR.

How asset managers voted at the SYNDAX PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 217 asset managers that disclosed a SYNDAX PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Jennifer Jarrett

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

63% Majority: yes · of votes cast

FOR 63%WITHHELD

FOR: 39,491,936WITHHELD: 23,121,400

Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Election of Directors: Jennifer Jarrett

SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Jennifer Jarrett”): 39,491,936 for, 23,121,400 withheld, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 16,535,343 for, 8,286,958 withheld.

FORWITHHOLD

FOR: 16,535,343WITHHOLD: 8,286,958

Largest asset managers voting on “Election of Directors: Jennifer Jarrett” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	8,905,246	0	For
BlackRock	3,561,811	0	For
State Street	3,133	3,196,274	Withhold
Fidelity	1,771,614	0	For
T. Rowe Price	14,587	1,353,833	Withhold
FRANKLIN STRATEGIC SERIES	761,451	0	For
Charles Schwab	0	634,277	Withhold
Columbia Threadneedle	0	470,690	Withhold
Hartford	450,188	0	For
JPMorgan	0	409,750	Withhold
TIAA	0	390,922	Withhold
Federated Hermes	354,664	0	For
Direxion Shares ETF Trust	0	219,075	Withhold
Equitable	121,199	76,160	Mixed
John Hancock	96,114	93,926	Mixed
Delaware/Macquarie	0	180,000	Withhold
QUANTITATIVE MASTER SERIES LLC	138,102	0	For
Exchange Place Advisors Trust	0	137,480	Withhold
Brighthouse	33,027	100,438	Mixed
Dimensional	0	103,530	Withhold
Prudential/PGIM	56,452	39,202	Mixed
Allspring	0	94,139	Withhold
AIG/SunAmerica	0	94,025	Withhold
Victory Capital	1,653	77,970	Withhold
Lincoln Financial	0	75,145	Withhold

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

2. Elect Director: Martin H. Huber, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 61,876,711WITHHELD: 736,625

Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Election of Directors: Martin H. Huber, M.D.

SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Martin H. Huber, M.D.”): 61,876,711 for, 736,625 withheld, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 24,585,931 for, 236,370 withheld.

FOR

FOR: 24,585,931WITHHOLD: 236,370

Largest asset managers voting on “Election of Directors: Martin H. Huber, M.D.” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	8,905,246	0	For
BlackRock	3,561,811	0	For
State Street	3,199,027	380	For
Fidelity	1,740,912	30,702	For
T. Rowe Price	1,368,420	0	For
FRANKLIN STRATEGIC SERIES	761,451	0	For
Charles Schwab	634,277	0	For
Columbia Threadneedle	470,690	0	For
Hartford	450,188	0	For
JPMorgan	409,750	0	For
TIAA	390,922	0	For
Federated Hermes	354,664	0	For
Direxion Shares ETF Trust	219,075	0	For
Equitable	121,199	76,160	Mixed
John Hancock	190,040	0	For
Delaware/Macquarie	180,000	0	For
QUANTITATIVE MASTER SERIES LLC	138,102	0	For
Exchange Place Advisors Trust	137,480	0	For
Brighthouse	115,725	17,740	Mixed
Dimensional	0	103,530	Withhold
Prudential/PGIM	95,654	0	For
Allspring	94,139	0	For
AIG/SunAmerica	94,025	0	For
Victory Capital	79,623	0	For
Lincoln Financial	75,145	0	For

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

3. Elect Director: William Meury

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%

FOR: 54,416,889WITHHELD: 8,196,447

Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Election of Directors: William Meury

SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: William Meury”): 54,416,889 for, 8,196,447 withheld, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 20,578,485 for, 4,243,816 withheld.

FORWITHHOLD

FOR: 20,578,485WITHHOLD: 4,243,816

Largest asset managers voting on “Election of Directors: William Meury” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Withheld	Vote
Vanguard	8,905,246	0	For
BlackRock	0	3,561,811	Withhold
State Street	3,199,027	380	For
Fidelity	1,691,352	80,262	For
T. Rowe Price	1,368,420	0	For
FRANKLIN STRATEGIC SERIES	761,451	0	For
Charles Schwab	634,277	0	For
Columbia Threadneedle	470,690	0	For
Hartford	450,188	0	For
JPMorgan	409,750	0	For
TIAA	390,922	0	For
Federated Hermes	354,664	0	For
Direxion Shares ETF Trust	219,075	0	For
Equitable	0	197,359	Withhold
John Hancock	190,040	0	For
Delaware/Macquarie	180,000	0	For
QUANTITATIVE MASTER SERIES LLC	0	138,102	Withhold
Exchange Place Advisors Trust	137,480	0	For
Brighthouse	115,725	17,740	Mixed
Dimensional	0	103,530	Withhold
Prudential/PGIM	95,654	0	For
Allspring	94,139	0	For
AIG/SunAmerica	94,025	0	For
Victory Capital	79,623	0	For
Lincoln Financial	75,145	0	For

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

4. 2. Advisory vote on executive compensation

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 8 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%AGAINST

FOR: 46,228,421AGAINST: 16,304,796

Details: description as filed, official tally, votes by 214 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE 2024 PROXY STATEMENT.

SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory vote on executive compensation”): 46,228,421 for, 16,304,796 against, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 69 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN ” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Withheld	Vote
Vanguard	4,655,894	4,249,352	0	0	Mixed
BlackRock	3,561,811	0	0	0	For
State Street	3,199,407	0	0	0	For
Fidelity	1,771,614	0	0	0	For
T. Rowe Price	1,368,420	0	0	0	For
FRANKLIN STRATEGIC SERIES	761,451	0	0	0	For
Charles Schwab	0	634,277	0	0	Against
Columbia Threadneedle	470,690	0	0	0	For
Hartford	0	450,188	0	0	Against
JPMorgan	409,750	0	0	0	For
TIAA	390,922	0	0	0	For
Federated Hermes	354,664	0	0	0	For
Direxion Shares ETF Trust	219,075	0	0	0	For
Equitable	197,359	0	0	0	For
John Hancock	93,926	96,114	0	0	Mixed
Delaware/Macquarie	180,000	0	0	0	For
QUANTITATIVE MASTER SERIES LLC	138,102	0	0	0	For
Exchange Place Advisors Trust	0	137,480	0	0	Against
Brighthouse	82,698	33,027	17,740	0	Mixed
Dimensional	0	103,530	0	0	Against
Prudential/PGIM	39,202	56,452	0	0	Mixed
Allspring	94,139	0	0	0	For
AIG/SunAmerica	94,025	0	0	0	For
Victory Capital	77,970	1,653	0	0	For
Simplify Exchange Traded Funds	25,625	0	0	50,000	Mixed

Fund voting reports, all 69 managers: 18,901,000 for, 5,929,186 against, 50,000 withheld, 17,740 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 168 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN ” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Withheld	Vote
Wellington	0	7,027,115	0	Against
Kynam Capital Management, LP	0	0	5,660,000	Withhold
State Street	4,702,965	0	0	For
Eversept Partners, LP	3,225,997	0	0	For
BlackRock	3,060,713	0	0	For
T. Rowe Price	2,404,591	0	0	For
MARSHALL WACE, LLP	0	2,048,017	0	Against
BVF INC/IL	1,875,000	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,781,607	0	0	For
Avidity Partners Management LP	0	1,752,627	0	Against
ORBIMED ADVISORS LLC	0	1,749,000	0	Against
FRANKLIN ADVISERS INC	1,394,514	0	0	For
Aisling Capital Management LP	1,025,000	0	0	For
Candriam S.C.A.	999,934	0	0	For
Sofinnova Investments, Inc.	930,287	0	0	For
ADAGE CAPITAL PARTNERS GP, L.L.C.	900,000	0	0	For
KINGDON CAPITAL MANAGEMENT, L.L.C.	0	887,094	0	Against
Foresite Capital Management IV, LLC	875,000	0	0	For
JPMorgan	696,623	0	0	For
Northern Trust	668,691	44	0	For
DAFNA Capital Management LLC	665,574	0	0	For
PFM Health Sciences, LP	658,694	0	0	For
Charles Schwab	0	634,381	0	Against
Palo Alto Investors LP	472,600	0	0	For
Avoro Capital Advisors LLC	437,716	0	0	For

Institutional-manager reports, all 168 managers: 32,538,950 for, 15,673,792 against, 5,660,000 withheld, 1,394 abstained, 175 not voted. Showing the 25 largest; see all in the interactive database.

5. 3. Ratification of selection of independent registered public accounting firm

Outcome not verifiedAUDIT-RELATEDReported outcome: Not verified

Combines 2 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%

FOR: 65,371,337AGAINST: 253,270

Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

SYNDAX PHARMACEUTICALS INC.’s own tally for this item (“3. Ratification of selection of independent registered public accounting firm”): 65,371,337 for, 253,270 against, per its Form 8-K filed May 15, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 24,803,846 for, 715 against, 17,740 abstained.

FOR

FOR: 24,803,846AGAINST: 715ABSTAIN: 17,740

Largest asset managers voting on “TO RATIFY THE SELECTION OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE C” at SYNDAX PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	8,905,246	0	0	For
BlackRock	3,561,811	0	0	For
State Street	3,198,901	506	0	For
Fidelity	1,771,614	0	0	For
T. Rowe Price	1,368,420	0	0	For
FRANKLIN STRATEGIC SERIES	761,451	0	0	For
Charles Schwab	634,277	0	0	For
Columbia Threadneedle	470,690	0	0	For
Hartford	450,188	0	0	For
JPMorgan	409,750	0	0	For
TIAA	390,922	0	0	For
Federated Hermes	354,664	0	0	For
Direxion Shares ETF Trust	219,075	0	0	For
Equitable	197,359	0	0	For
John Hancock	190,040	0	0	For
Delaware/Macquarie	180,000	0	0	For
QUANTITATIVE MASTER SERIES LLC	138,102	0	0	For
Exchange Place Advisors Trust	137,480	0	0	For
Brighthouse	115,725	0	17,740	Mixed
Dimensional	103,530	0	0	For
Prudential/PGIM	95,654	0	0	For
Allspring	94,139	0	0	For
AIG/SunAmerica	94,025	0	0	For
Victory Capital	79,623	0	0	For
Lincoln Financial	75,145	0	0	For

Showing the 25 largest of 68 asset managers. See all 68 in the interactive database.

Largest SYNDAX PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 84,979,686 shares outstanding at the time of that meeting.

Fund voting reports: top SYNDAX PHARMACEUTICALS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Vanguard	10.48%
2	BlackRock	4.19%
3	State Street	3.76%
4	Fidelity	2.08%
5	T. Rowe Price	1.61%
6	FRANKLIN STRATEGIC SERIES	0.90%
7	Charles Schwab	0.75%
8	Columbia Threadneedle	0.55%
9	Hartford	0.53%
10	JPMorgan	0.48%

Institutional-manager reports: top SYNDAX PHARMACEUTICALS INC. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS…”, 2023-2024
#	Asset manager	% of shares outstanding
1	Wellington	8.27%
2	Kynam Capital Management, LP	6.66%
3	State Street	5.53%
4	Eversept Partners, LP	3.80%
5	BlackRock	3.60%
6	T. Rowe Price	2.83%
7	MARSHALL WACE, LLP	2.41%
8	BVF INC/IL	2.21%
9	GEODE CAPITAL MANAGEMENT, LLC	2.10%
10	Avidity Partners Management LP	2.06%

Reported SYNDAX PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

SYNDAX PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
BlackRock	10.15%	13F
Entities affiliated with Wellington Group, LLP.	8.93%	DEF14A
Wellington Management	8.75%	13F
Entities affiliated with BlackRock, Inc.	8.26%	DEF14A
Entities affiliated with Kynam Capital Management, LP	6.66%	DEF14A
Goldman Sachs	6.46%	13F
Vanguard Group	6.05%	13F
State Street	5.67%	13F
S	4.65%	13G
Point72	2.43%	13F

Percentages above are of 84,979,686 shares outstanding, as reported by SYNDAX PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SYNDAX PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.

At SYNDAX PHARMACEUTICALS INC.'s shareholder meeting held May 15, 2024, in the 2023-2024 proxy season, 217 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,261 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS… — FOR was 74% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: SYNDAX PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 15, 2024.

SYNDAX PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.